

Petra Baji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8569655/publications.pdf>

Version: 2024-02-01

82
papers

1,717
citations

279798

23
h-index

330143

37
g-index

90
all docs

90
docs citations

90
times ranked

2229
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	3.1	6
2	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	2.6	3
3	Examining obstetric interventions and respectful maternity care in Hungary: Do informal payments for continuity of care link to quality?. <i>Birth</i> , 2021, 48, 309-318.	2.2	7
4	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50â€“70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	2.8	4
5	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.3	6
6	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	1.3	1
7	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	2.4	3
8	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165.	2.5	4
9	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	3.1	13
10	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	3.3	6
11	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQIâ€™Relevant (DLQIâ€™R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	2.4	7
12	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	4.3	17
13	Understanding the use of patient-reported data by health care insurers: A scoping review. <i>PLoS ONE</i> , 2020, 15, e0244546.	2.5	4
14	Patient experiences in a public primary health care clinic: A South African case study. <i>Society and Economy</i> , 2020, 42, 333-347.	0.3	2
15	Title is missing!. , 2020, 15, e0235165.		0
16	Title is missing!. , 2020, 15, e0235165.		0
17	Title is missing!. , 2020, 15, e0235165.		0
18	Title is missing!. , 2020, 15, e0235165.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0235165.		0
20	Title is missing!. , 2020, 15, e0235165.		0
21	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
22	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
23	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
24	Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546.		0
25	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. European Journal of Health Economics, 2019, 20, 57-69.	2.8	49
26	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. European Journal of Health Economics, 2019, 20, 5-16.	2.8	22
27	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. European Journal of Health Economics, 2019, 20, 71-78.	2.8	17
28	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. European Journal of Health Economics, 2019, 20, 141-154.	2.8	12
29	Patient experiences with outpatient care in Hungary: results of an online population survey. European Journal of Health Economics, 2019, 20, 79-90.	2.8	10
30	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. European Journal of Health Economics, 2019, 20, 119-132.	2.8	17
31	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. European Journal of Health Economics, 2019, 20, 17-30.	2.8	11
32	Cost-of-illness studies in nine Central and Eastern European countries. European Journal of Health Economics, 2019, 20, 155-172.	2.8	23
33	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. European Journal of Health Economics, 2019, 20, 109-117.	2.8	8
34	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. Value in Health, 2019, 22, S794.	0.3	2
35	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry, 2019, 26, 259-269.	2.4	34
36	Long-term care financing in Europe: An overview. Zdrowie Publiczne I ZarzÄ...dzanie, 2019, 17, 131-145.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Adaptation or recovery after health shocks? Evidence using subjective and objective health measures. <i>Health Economics (United Kingdom)</i> , 2018, 27, 850-864.	1.7	12
38	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	3.8	20
39	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.6	19
40	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	2.4	4
41	Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	2.4	3
42	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	2.9	64
43	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	1.4	22
44	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	3.0	9
45	Informal cash payments for birth in Hungary: Are women paying to secure a known provider, respect, or quality of care?. <i>Social Science and Medicine</i> , 2017, 189, 86-95.	3.8	25
46	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	1.4	5
47	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	4.2	30
48	Access to biologicals in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	3.3	35
49	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	1.9	15
50	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	2.7	17
51	Assessing quality of maternity care in Hungary: expert validation and testing of the mother-centered prenatal care (MCPC) survey instrument. <i>Reproductive Health</i> , 2017, 14, 152.	3.1	9
52	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	1.4	44
53	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.5	144
54	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.5	15

#	ARTICLE	IF	CITATIONS
55	Health promotion targeting older people. BMC Health Services Research, 2016, 16, 345.	2.2	66
56	Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. European Journal of Health Economics, 2016, 17, 99-108.	2.8	31
57	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues, 2016, 10, 85-90.	1.2	11
58	EQ-5D in Central and Eastern Europe: 2000â€“2015. Quality of Life Research, 2016, 25, 2693-2710.	3.1	103
59	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. European Journal of Health Economics, 2016, 17, 89-98.	2.8	41
60	Patientsâ€™ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Annals of the Rheumatic Diseases, 2016, 75, 942-943.	0.9	21
61	Discrepancies between the Dermatology Life Quality Index and utility scores. Quality of Life Research, 2016, 25, 1687-1696.	3.1	16
62	Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. European Journal of Health Economics, 2016, 17, 791-799.	2.8	10
63	Treatment preferences of originator versus biosimilar drugs in Crohnâ€™s disease; discrete choice experiment among gastroenterologists. Scandinavian Journal of Gastroenterology, 2016, 51, 22-27.	1.5	30
64	The impact of the recession on health care expenditure â€” How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries?. Society and Economy, 2015, 37, 73-88.	0.3	1
65	Does the Implementation of Official User Charges Help to Eradicate Informal Payments â€” Lessons to be Learnt from the Hungarian Experience. Frontiers in Public Health, 2015, 3, 181.	2.7	4
66	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. British Journal of Dermatology, 2015, 173, 1076-1080.	1.5	24
67	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. Pathology and Oncology Research, 2015, 21, 619-627.	1.9	17
68	Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Review of Clinical Immunology, 2015, 11, 43-52.	3.0	83
69	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. PLoS ONE, 2014, 9, e107704.	2.5	31
70	Acceptability of less than perfect health states in rheumatoid arthritis: the patientsâ€™ perspective. European Journal of Health Economics, 2014, 15, 73-82.	2.8	12
71	The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. European Journal of Health Economics, 2014, 15, 853-867.	2.8	13
72	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 27-34.	2.8	14

#	ARTICLE	IF	CITATIONS
73	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. <i>European Journal of Health Economics</i> , 2014, 15, 45-52.	2.8	27
74	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	2.8	26
75	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71.	2.8	108
76	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109.	2.8	22
77	Exploring consumers' attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary. <i>BMC Health Services Research</i> , 2013, 13, 62.	2.2	33
78	Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. <i>Society and Economy</i> , 2012, 34, 221-240.	0.3	9
79	Preferences of Hungarian consumers for quality, access and price attributes of health care services – result of a discrete choice experiment. <i>Society and Economy</i> , 2012, 34, 293-311.	0.3	7
80	Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary. <i>International Journal for Equity in Health</i> , 2012, 11, 36.	3.5	36
81	Informal payments for healthcare services and short-term effects of the introduction of visit fee on these payments in Hungary. <i>International Journal of Health Planning and Management</i> , 2012, 27, 63-79.	1.7	48
82	User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders. <i>Health Policy</i> , 2011, 102, 255-262.	3.0	44